gurufocus.comSEP 101 min read$MCK

McKesson Corp (MCK) Insider Sale: SVP, Controller & CAO Rutledge

McKesson Corp (MCK) SVP, Controller & CAO Rutledge sold 111 shares on 2026-09-08, reducing holdings to 521 shares. Over the past year, Rutledge sold 901 shares with no purchases, part of a broader pattern of 17 insider sells and 0 buys. McKesson, a healthcare services company, trades at $891.45 with a P/E of 23.65, deemed fairly valued by GuruFocus's GF Value.

Original reporting

gurufocus.com

Published Sep 10, 2026, 8:37 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 11, 2026, 5:58 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$MCK

Bearish

medium confidence

Mentioned

$MCK

Relevance

4/10

AlphAI data visualization · based on gurufocus.com

Decision brief

The 30-second read

$MCKBearishLow

Why it matters

The disclosed sale adds to a pattern of insider divestment, but guru accumulation offsets negative signal.

Market read

Routine insider sale with modest size; limited trading relevance.

What to watch

Potential tax or liquidity reasons for sale; guru buying suggests confidence.

Relevance 4/10Novelty 4/10Timing: sale reported on Sep 8 2026

Background

McKesson is a large healthcare distribution company; insider activity is routinely monitored.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MCKBearishMedium confidence

Context

Form 4 disclosed SVP Rutledge sold 111 shares (~$99k) on 2026-09-08, adding to a year‑long pattern of insider selling.

Expected impact

Potential marginal downward pressure, likely within normal volatility.

Evidence & confidence

Insider is a senior executive; sale amount is modest relative to market cap; no other catalyst present.

Market effects

Sector

None; healthcare distribution sector unchanged.

Regional

No regional effect beyond MCK.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

Insider selling could be unrelated to fundamentals; investors may ignore.

Key entities

Individual
Rutledge Napoleon B JR
Senior Vice President, Controller & Chief Accounting Officer of McKesson
Company
McKesson Corp
Healthcare distribution and services firm (ticker MCK)

Read at source ← All news

SEP 15

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

simplywall.st3 min

SEP 14

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

yahoo.com2 min

SEP 8

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

yahoo.com6 min

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 6

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

yahoo.com3 min

SEP 5

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.